Vyome Holdings, Inc. develops clinical-stage specialty pharmaceutical therapies for immune-inflammatory and rare conditions. Company news centers on VT-1953, a topical gel program for malodor and other symptoms of malignant fungating wounds in cancer patients, and VT-1908, a repurposed immune modulator being studied for uveitis.
Recurring updates include clinical and preclinical data presentations, regulatory submissions and development planning, capital-structure actions, material agreements, shareholder voting matters, and operating or financial results tied to Vyome’s pharmaceutical and biotechnology activities.
Vyome Holdings (Nasdaq: HIND) received a USPTO Notice of Allowance covering formulations and methods of use underlying its VT-1908 ocular inflammation program. The allowed claims relate to U.S. Patent Application No. 17/787,303. VT-1908 is a topical eye formulation of mycophenolate, a drug that modifies immune activity, being developed initially for anterior uveitis, an inflammatory eye condition.
Preclinical results published in February 2026 in the Journal of Ophthalmic Inflammation and Infection showed therapeutic drug concentrations in the eye, reduced inflammation in a uveitis model, and efficacy comparable to topical steroids. Vyome envisions development for a broader range of ocular and periocular inflammatory conditions beyond its initial uveitis focus.
Vyome Holdings (HIND) appointed veteran finance executive Jerry Leonard, CPA, MBA, as Chief Financial Officer effective September 1, 2026.
Leonard will oversee Vyome’s financial operations, reporting, accounting, internal controls and related corporate governance. He succeeds Robert Dickey IV, who had served as Interim CFO since August 2025. The company highlights Leonard’s more than 25 years of experience in financial management, business leadership and corporate strategy.
Leonard is founder and CEO of ClearBridgeCFO and previously served as SVP, CFO and Secretary of VSee Health after its 2024 business combination, and as CFO of iDoc Virtual Telehealth Solutions and VSee Lab. Earlier roles included finance leadership positions at Voya Financial, IBM and Colgate-Palmolive, following an early career in public accounting at Arthur Andersen and PwC.
Vyome Holdings (Nasdaq: HIND) reported second quarter 2026 results and clinical progress for lead candidate VT-1953 for malignant fungating wounds. Phase 2 data showed statistically significant improvements in malodor, patient-reported impact on daily life, and lesion pain, with no treatment-emergent adverse events.
In March 2026, Vyome submitted a pre-IND briefing package to the FDA outlining a proposed pivotal study strategy and received written feedback in the second quarter. The company is preparing additional materials and plans a Type C meeting to further advance VT-1953. Vyome also in-licensed two selective JAK inhibitor assets from Impetis Biosciences and obtained a granted Chinese patent for VB-1953 in inflammatory acne.
As of June 30, 2026, cash and cash equivalents were approximately $7.9 million versus $5.0 million at year-end 2025. Second quarter 2026 operating expenses were about $874,000, and net loss attributable to common shareholders was approximately $720,000, or $0.10 per share.
Vyome (NASDAQ:HIND) received a new Chinese patent covering formulation and therapeutic use claims for its besifloxacin topical gel for inflammatory acne. The patent broadens protection to acne, associated inflammation, and antibiotic-resistant Propionibacterium acnes in China, an estimated $600 million prescription acne market, supporting future partnering and regional commercialization.
Vyome Holdings (Nasdaq:HIND) reported Q1 2026 results and regulatory progress. The company ended the quarter with approximately $8.8 million in cash and no debt, preferred stock, or toxic financing instruments. Net loss was about $963,000, or $0.15 per share.
Vyome advanced VT-1953 toward pivotal readiness, submitted an FDA Orphan Drug Designation application, and presented positive Phase 2 data. It also in-licensed selective JAK inhibitor assets from Impetis Biosciences and raised roughly $5.29 million in equity, implying around 15% dilution.
Vyome (Nasdaq: HIND) presented Phase 2 data showing VT-1953 gel produced statistically significant reductions in malignant fungating wound (MFW) malodor and pain by Day 14 (primary endpoint: median TELER score improved from 0.5 to 4; P=0.0020).
Additional highlights: superiority versus vehicle (P=0.0015), 70% of VT-1953 patients reported improved malodor impact versus 0% for vehicle (P=0.0256), a 2-point median pain improvement (P=0.0020), and no treatment-emergent adverse effects reported.
Vyome (Nasdaq: HIND) will present complete Phase 2 clinical and supporting preclinical data for VT-1953 as a potential treatment for malodor and symptoms of malignant fungating wounds (MFW) at AACR 2026 on April 21, 2026.
Vyome said VT-1953 is first-in-class with a dual mechanism (DNA Gyr inhibition and MD2/TLR modulation). The company plans FDA interactions in Q2 2026 and is advancing VT-1953 toward pivotal studies; third-party analysts estimate a ~USD 2.2 billion U.S. TAM. MFW affects ~10% of advanced cancer patients.
Vyome (Nasdaq: HIND) completed a streamlined Nasdaq listing via merger, holds a clean capital structure with 5,919,337 common shares and no preferred stock or debt. Final Phase 2 data for VT-1953 showed statistically significant malodor reduction (P<0.002) and favorable safety.
Total cash was approximately $4.94M at 12/31/2025 plus an $5.3M ATM financing in Jan 2026, supporting runway to mid-2027; independent valuation placed VT-1953 at ~$1B post-Phase 3.
Livechain (subsidiary of Vyome; Nasdaq: HIND) acquired senior, secured convertible debt of Humanyze via an all‑stock purchase and initiated a default and asset transfer to assume Humanyze's business assets and operations.
Livechain issued common stock valued at approximately $325,000 to Remus Capital and said the deal creates a path to seek a possible uplisting to a national exchange in 2026.
Vyome (Nasdaq: HIND) announced publication of preclinical results showing topical VT-1908 reduced uveitis scores (p<0.001) and lowered anterior chamber lymphocytes with no irritation or toxicity in an animal model. VT-1908 matched topical prednisone in efficacy preclinically. The company plans to advance VT-1908 into human studies via the India innovation corridor while keeping its capital deployment unchanged and maintaining focus on the Phase 3 program for lead asset VT-1953.